Gerd has more than 30 years of international leadership experience in biopharm including as CEO of Intercell (now Valneva) and MD of Chiron-Behring. He also held senior roles in R&D and Technical Operations at Chiron and Behringwerke. Since 2012 he has served on the Board of Directors of several non-profit organizations and biotech companies, including as chairman of GlycoVaxyn and Themis, both of which were sold to big pharma during his tenure. He holds a doctoral degree in biochemistry from the University of Regensburg and carried out a post-doctoral fellowship at the Institut Pasteur Paris in virology.

Current positions: Chairman of the Board at Medigene AG.

Emmanuelle is Partner in the Seed Investment team at Novo Holdings, with over 16 years’ experience as a life science venture investor. Prior to Novo Seeds, Emmanuelle was Partner at Auriga Partners and oversaw the Seed Stage Investment Programme at Omnes Capital (formerly Crédit Agricole Private Equity). Emmanuelle has a PhD in Microbiology from the Universite Paris Cite and an MSM, Medical management from ESCP Business School.

Current positions: Member of the Board of Directors of Draupnir, Corwave, Heparegenix, and BiOrigin.

Sten is a founding partner at Sunstone Capital A/S. He has more than 30 years of experience as an international executive, entrepreneur, and venture investor in biotech companies and pre-clinical and clinical CROs. Sten holds an M.Sc. in Biology and a Ph.D. in Immunology from the University of Copenhagen.

Current positions: Chairman of the Board at Neumirna, Member of the Board of Stipe Therapeutics

Patrik is Practice Lead Deep Tech and Senior Investment Director at Industrifonden, having joined the organisation in 2016. Previously he held leading roles at IMS Health, GlaxoSmithKline and AstraZeneca and was part of the team building, scaling and successfully selling United Health Group and IMS Health. Patrik is an Associated Professor in Health Economics and Epidemiology at the Karolinksa Institute and has published over 40 scientific articles. He has an MSc in Finance from the Stockholm School of Economics, an MA in international management from the Community of European Management Schools and a PhD in Medicine from the Karolinska Institute.

Current positions: Member of the Board at Pixelgen Technologies, EnginZyme, NuvoAir, Onocopeptides, Combinostics, BCB Medical, Trialbee, AMRA Medical, Calliditas, European Innovation Council and SMEs Executive Agency (EISMEA)

Regina is a managing Partner and senior investment manager at Wellington Partners having joined in 2010. Previously, she led the European life sciences efforts at Boston-based Atlas Venture, was an Investment Manager at Apax Partners and a consultant at McKinsey where she founded McKinsey’s New Venture Initiative. Regina is an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences with over 25 investments and successful exits incl. Themis, Rigontec, Sapiens Medical, Middle Peak Medical, and Bicycle Therapeutics. She has a PhD in biochemistry, and was a post-doctoral researcher at the MRC, Cambridge UK.

Current positions: Member of the Board at Sidekick Health, Stipe Therapeutics, SIPR Biome, Carisma Therapeutics and TriCares.

Kabeer is a Partner at Adjuvant Capital, a life sciences investment fund designed to accelerate the development of new technologies for the world’s most pressing public health challenges. He is based in New York. Prior to Adjuvant, Kabeer was with the Global Health Investment Fund (GHIF), where he led investments in biotech companies addressing unmet needs in infectious disease and maternal and child health. Before GHIF, Kabeer spent time at Metalmark Capital investing across the healthcare sector, as well as at Greenhill & Co., where he advised on biopharmaceutical M&A transactions. Kabeer graduated with honors from the Stern School of Business at New York University.

Current positions: Member of the Board of Directors of AN2 Therapeutics (NASDAQ: ANTX), Pulmocide, and Frontier Nutrition, while previously supporting Adjuvant’s engagement on the Board of Themis (acquired by MSD); vice president and secretary of Adjuvant Global Health Technology Fund.

Christopher is a Principal at Sanofi Ventures. Prior to joining Sanofi Ventures, he was a management consultant at L.E.K. Consulting, where his work focused on corporate strategy, due diligence, commercial launch planning, and asset valuation across the pharmaceutical, biotech, R&D, and API manufacturing sectors. Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill and graduated with honors from Roger Williams University.

Current positions: Member of the Board of Directors of I2O Therapeutics and Sudo Bio, and a Board Observer at Matchpoint, NextPoint, Avilar.

Veronica has been a Partner at Pureos Bioeventures since 2022. Prior to joining Pureos, she co-founded and was CEO of LimmaTech Biologics and GlycoEra AG. Veronica started her career in the MedTech field, focused on clinical R&D and international regulatory. In 2009, she moved to the vaccine company GlycoVaxyn where she held roles in clinical, regulatory, and business development, and was one of the core members responsible for building GlycoVaxyn’s success and acquisition by GSK in 2015. Veronica holds a degree in engineering and a PhD in life sciences in the field of cardiovascular disease.

Current positions: Member of Board of Directors of Memo Therapeutics.

Bita is a Senior Director focusing on Ventures at Trill Impact and has more than 15 years of experience from both life science R&D and venture capital. Prior roles include Investment Director at Industrifonden, Head of Business Development and Strategic Partnerships for Battat Inc., and as a consultant at Caisse de dépôt et placement du Québec, the Canadian investment fund, and Foster Rosenblatt Consulting. She holds a Master of Science in Biomedicine, a Ph.D. in molecular oncology from Karolinska Institute and has an MBA from Concordia University John Molsen School of Business. She also held post-doctoral fellowships at Karolinska Institute and McGill University.

Vincent is a Venture Partner within the EQT Life Sciences team. Vincent worked for LSP from 2016 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Previously, Vincent was Senior Vice-President and member of the Executive Committee at GSK Biologicals. Vincent holds an M.D., specializes in oncology, has a Ph.D. from the Ludwig Institute for Cancer Research, has been a researcher with the FNRS/NFWO and holds an exec MBA from the Harvard Business School. Vincent has more than 90 primary research publications and reviews in the fields of immuno-oncology, auto-immunity, and vaccines.

Tal is a Partner with OrbiMed. Tal was recently the Chief Medical Officer at Moderna, where he led the development of the company’s COVID-19 vaccine and other key programs. Previously, Tal held senior leadership positions in drug development at major pharmaceutical companies, including Sanofi and GlaxoSmithKline. Tal received his M.D. and Ph.D. from the Ben Gurion University and conducted post-doctoral research at the U.S. National Institutes of Health.

Current positions: Executive chairman of Exsilio.